{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:36:14Z","timestamp":1794278174037,"version":"4.9.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1245\/s10434-023-13932-3","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T08:09:59Z","timestamp":1691654999000},"page":"8115-8137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer"],"prefix":"10.1245","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-6898","authenticated-orcid":false,"given":"Aditi","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Nadeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemien","family":"Van Driel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoual","family":"Bakrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"issue":"2","key":"13932_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000521239","volume":"38","author":"A Bhatt","year":"2022","unstructured":"Bhatt A, Glehen O. Hyperthermic intraperitoneal chemotherapy in the treatment armamentarium of epithelial ovarian cancer: time to end the dichotomy. Visc Med. 2022;38(2):109\u201319. https:\/\/doi.org\/10.1159\/000521239. (Epub 2022).","journal-title":"Visc Med."},{"issue":"14","key":"13932_CR2","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.3390\/cancers13143430","volume":"13","author":"RFCPA Helderman","year":"2021","unstructured":"Helderman RFCPA, L\u00f6ke DR, Tanis PJ, Tuynman JB, Ceelen W, de Hingh IH, van der Speeten K, Franken NAP, Oei AL, Kok HP, Crezee J. Preclinical in vivo-models to investigate HIPEC; current methodologies and challenges. Cancers (Basel). 2021;13(14):3430. https:\/\/doi.org\/10.3390\/cancers13143430.","journal-title":"Cancers (Basel)."},{"issue":"13","key":"13932_CR3","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.1245\/s10434-021-10205-9","volume":"28","author":"A Bhatt","year":"2021","unstructured":"Bhatt A, Van Der Speeten K, Hubner M, Kusamura S, Glehen O. ASO Author reflections: standardizing HIPEC methodology and regimens: a prelude to the PSOGI expert consensus. Ann Surg Oncol. 2021;28(13):9114\u20135. https:\/\/doi.org\/10.1245\/s10434-021-10205-9. (Epub 2021 Jun 4 PMID: 34089108).","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"13932_CR4","doi-asserted-by":"publisher","first-page":"9098","DOI":"10.1245\/s10434-021-10193-w","volume":"28","author":"A Bhatt","year":"2021","unstructured":"Bhatt A, de Hingh I, Van Der Speeten K, Hubner M, Deraco M, Bakrin N, Villeneuve L, Kusamura S, Glehen O. HIPEC methodology and regimens: the need for an expert consensus. Ann Surg Oncol. 2021;28(13):9098\u2013113. https:\/\/doi.org\/10.1245\/s10434-021-10193-w. (Epub 2021 Jun 17 PMID: 34142293).","journal-title":"Ann Surg Oncol."},{"key":"13932_CR5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12990-3","author":"S Kusamura","year":"2023","unstructured":"Kusamura S, Bhatt A, Hubner M, Villeneuve L, Deraco M, Bakrin N, Van Der Speeten K, Glehen O. The PSOGI international consensus on HIPEC regimens for peritoneal malignancies: methodology. Ann Surg Oncol. 2023. https:\/\/doi.org\/10.1245\/s10434-022-12990-3.","journal-title":"Ann Surg Oncol."},{"key":"13932_CR6","doi-asserted-by":"publisher","first-page":"235e51","DOI":"10.1016\/0040-1625(91)90039-I","volume":"39","author":"G Rowe","year":"1991","unstructured":"Rowe G, Wright G, Bolger F. Delphi: a re-evaluation of research and theory. Technol Forecast Soc Change. 1991;39:235e51. https:\/\/doi.org\/10.1016\/0040-1625(91)90039-I.","journal-title":"Technol Forecast Soc Change."},{"issue":"1","key":"13932_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejso.2019.03.012","volume":"47","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Villeneuve L, Govaerts K, de Hingh IHJT, Moran BJ, Deraco M, Van der Speeten K, Glehen O, Kepenekian V, Kusamura S. List of PSOGI collaborators. The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on pseudomyxoma peritonei and peritoneal mesothelioma. Eur J Surg Oncol. 2021;47(1):4\u201310. https:\/\/doi.org\/10.1016\/j.ejso.2019.03.012. (Epub 2019 Mar 23 PMID: 30954350).","journal-title":"Eur J Surg Oncol."},{"key":"13932_CR8","doi-asserted-by":"publisher","first-page":"383e94","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Akl EA. GRADE guidelines: 1. Introduction e GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383e94. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026.","journal-title":"J Clin Epidemiol."},{"key":"13932_CR9","doi-asserted-by":"publisher","first-page":"1490e4","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Akinns","year":"2004","unstructured":"Akinns D, Best D, Briss PA, Eccles M, Falck-Ytter Y. Grades of Recommendation. Assessment, development, and evaluation (GRADE) working group. Education and debate e grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490e4. https:\/\/doi.org\/10.1136\/bmj.328.7454.1490.","journal-title":"BMJ"},{"issue":"11","key":"13932_CR10","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/bjs.5863","volume":"94","author":"RM Smeenk","year":"2007","unstructured":"Smeenk RM, Verwaal VJ, Zoetmulder FA. Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg. 2007;94(11):1408\u201314. https:\/\/doi.org\/10.1002\/bjs.5863. (PMID: 17631678).","journal-title":"Br J Surg."},{"issue":"5","key":"13932_CR11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","volume":"157","author":"MC Lim","year":"2022","unstructured":"Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY. HIPEC for ovarian cancer collaborators survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg. 2022;157(5):374\u201383. https:\/\/doi.org\/10.1001\/jamasurg.2022.0143.","journal-title":"JAMA Surg."},{"issue":"8","key":"13932_CR12","doi-asserted-by":"publisher","first-page":"e2013940","DOI":"10.1001\/jamanetworkopen.2020.13940","volume":"3","author":"Z Lei","year":"2020","unstructured":"Lei Z, Wang Y, Wang J, Wang K, Tian J, Zhao Y, Chen L, Wang J, Luo J, Jia M, Tang H, He Q, Liao Q, Yang X, Guan T, Wang L, Cui S. Chinese Peritoneal Oncology Study Group. (Gynecologic Oncology Study Group) Evaluation of cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer. JAMA Netw Open. 2020;3(8):e2013940. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.13940.","journal-title":"JAMA Netw Open."},{"issue":"3","key":"13932_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, van Schagen Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1708618. (PMID: 29342393).","journal-title":"N Engl J Med."},{"issue":"4","key":"13932_CR14","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1245\/s10434-015-4991-4","volume":"23","author":"G Baiocchi","year":"2016","unstructured":"Baiocchi G, Ferreira FO, Mantoan H, da Costa AA, Faloppa CC, Kumagai LY, de Mello CA, Takahashi RM, Nakagawa WT, Aguiar S Jr, Lopes A. Hyperthermic intraperitoneal chemotherapy after primary cytoreduction in epithelial ovarian cancer: a single-center comparative analysis. Ann Surg Oncol. 2016;23(4):1294\u2013301. https:\/\/doi.org\/10.1245\/s10434-015-4991-4. (Epub 2015 Dec 1).","journal-title":"Ann Surg Oncol."},{"key":"13932_CR15","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","volume":"127","author":"A Fagotti","year":"2012","unstructured":"Fagotti A, Costantini B, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two-year follow-up. Gynecol Oncol. 2012;127:502\u20135.","journal-title":"Gynecol Oncol."},{"issue":"11","key":"13932_CR16","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1245\/s10434-014-3693-7","volume":"21","author":"JF Le Brun","year":"2014","unstructured":"Le Brun JF, Campion L, Berton-Rigaud D, Lorimier G, Marchal F, Ferron G, Oger AS, Dravet F, Jaffre I, Classe JM. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study. Ann Surg Oncol. 2014;21(11):3621\u20137. https:\/\/doi.org\/10.1245\/s10434-014-3693-7.","journal-title":"Ann Surg Oncol."},{"key":"13932_CR17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12094-009-0438-3","volume":"11","author":"FC Munoz-Casares","year":"2009","unstructured":"Munoz-Casares FC, Rufian S, Rubio MJ, et al. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol. 2009;11:753\u20139.","journal-title":"Clin Transl Oncol."},{"issue":"5","key":"13932_CR18","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","volume":"22","author":"J Spiliotis","year":"2015","unstructured":"Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570\u20135. https:\/\/doi.org\/10.1245\/s10434-014-4157-9. (Epub 2014 Nov 13 PMID: 25391263).","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"13932_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.31557\/APJCP.2019.20.2.621","volume":"20","author":"G Amira","year":"2019","unstructured":"Amira G, Morsi A, Fayek IS, Mansour O, Nader H. Hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in recurrent platinum-sensitive ovarian cancer NCI case control study. Asian Pac J Cancer Prev. 2019;20(2):621\u20137. https:\/\/doi.org\/10.31557\/APJCP.2019.20.2.621. (PMID:30806069 PMCID: PMC6897027).","journal-title":"Asian Pac J Cancer Prev."},{"issue":"6","key":"13932_CR20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/jso.23688","volume":"110","author":"T Safra","year":"2014","unstructured":"Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, Matceyevsky D, Weizman A, Klausner JM. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study. J Surg Oncol. 2014;110(6):661\u20135. https:\/\/doi.org\/10.1002\/jso.23688. (Epub 2014 Jun 24).","journal-title":"J Surg Oncol."},{"issue":"1","key":"13932_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1754-9493-6-12","volume":"6","author":"R Warschkow","year":"2012","unstructured":"Warschkow R, Tarantino I, Lange J, M\u00fcller SA, Schmied BM, Z\u00fcnd M, Steffen T. Does hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patients. Patient Saf Surg. 2012;6(1):12. https:\/\/doi.org\/10.1186\/1754-9493-6-12. (PMID: 22709648 PMCID: PMC3407737).","journal-title":"Patient Saf Surg."},{"issue":"23","key":"13932_CR22","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.21.00605","volume":"39","author":"O Zivanovic","year":"2021","unstructured":"Zivanovic O, Chi DS, Zhou Q, Iasonos A, Konner JA, Makker V, Grisham RN, et al. Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK Team Ovary phase II study. J Clin Oncol. 2021;39(23):2594\u2013604. https:\/\/doi.org\/10.1200\/JCO.21.00605. (Epub 2021 May 21 PMID: 34019431 PMCID: PMC8330970).","journal-title":"J Clin Oncol."},{"key":"13932_CR23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/02656730500307298","volume":"21","author":"JR Lepock","year":"2005","unstructured":"Lepock JR. How do cells respond to their thermal environment? Int J Hyperthermia. 2005;21:681\u20137.","journal-title":"Int J Hyperthermia."},{"key":"13932_CR24","first-page":"53","volume":"169","author":"E De Bree","year":"2007","unstructured":"De Bree E, Tsiftsis DD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: from laboratory bench to bedside. Recent Results Cancer Res. 2007;169:53\u201373.","journal-title":"Recent Results Cancer Res."},{"key":"13932_CR25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00685503","volume":"28","author":"G Los","year":"1991","unstructured":"Los G, Verdegaal EM, Mutsaers PH, McVie JG. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159\u201365.","journal-title":"Cancer Chemother Pharmacol."},{"key":"13932_CR26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0959-8049(97)00370-5","volume":"34","author":"PJ Van De Vaart","year":"1998","unstructured":"Van De Vaart PJ, Van Der Vange N, Zoetmulder FA, Van Goethem AR, Van Tellingen O, Ten Bokkel Huinink WW, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998;34:148\u201354.","journal-title":"Eur J Cancer."},{"key":"13932_CR27","unstructured":"Hettinga VE (1996) Reduction of cisplatin resistance by hyperthermia (PhD Thesis, Univ. of Groningen, ISBN 90-367-0648-3) (Printpartners Ipskamp bv, Enschede)"},{"key":"13932_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bpobgyn.2021.06.004","volume":"78","author":"LMC Vos","year":"2022","unstructured":"Vos LMC, Aronson SL, van Driel WJ, Huitema ADR, Schagen van Leeuwen JH, Lok CAR, Sonke GS. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2022;78:86. https:\/\/doi.org\/10.1016\/j.bpobgyn.2021.06.004. (Epub 2021 Aug 4 PMID: 34565676).","journal-title":"Best Pract Res Clin Obstet Gynaecol."},{"key":"13932_CR29","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/bjc.1997.297","volume":"75","author":"VE Hetting","year":"1997","unstructured":"Hetting VE, Lemstra W, Meijer C, et al. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin sensitive and -resistant tumor cells. Br J Cancer. 1997;75:1735\u201343.","journal-title":"Br J Cancer."},{"issue":"2","key":"13932_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ygyno.2016.05.032","volume":"142","author":"S Gouy","year":"2016","unstructured":"Gouy S, Ferron G, Glehen O, Bayar A, Marchal F, Pomel C, Quenet F, Bereder JM, Le Deley MC, Morice P. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. Gynecol Oncol. 2016;142(2):237\u201342. https:\/\/doi.org\/10.1016\/j.ygyno.2016.05.032. (Epub 2016 Jun 2).","journal-title":"Gynecol Oncol."},{"key":"13932_CR31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/ijc.29011","volume":"136","author":"O Zivanovic","year":"2015","unstructured":"Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T, et al. HIPEC ROC I: a phase 1 study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer. 2015;136:699\u2013708. https:\/\/doi.org\/10.1002\/ijc.29011.","journal-title":"Int J Cancer."},{"key":"13932_CR32","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/0006-2952(93)90472-9","volume":"46","author":"G Los","year":"1993","unstructured":"Los G, Van Vugt MJH, Den Engelse L, Pinedo HM. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochem Pharamcol. 1993;46:1229\u201337.","journal-title":"Biochem Pharamcol."},{"issue":"2","key":"13932_CR33","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s002800050870","volume":"43","author":"MA Steller","year":"1999","unstructured":"Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR, Dedrick RL. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol. 1999;43(2):106\u201314. https:\/\/doi.org\/10.1007\/s002800050870. (PMID: 9923815).","journal-title":"Cancer Chemother Pharmacol."},{"issue":"4","key":"13932_CR34","doi-asserted-by":"publisher","first-page":"20200137","DOI":"10.1515\/pp-2020-0137","volume":"5","author":"MS Mikkelsen","year":"2020","unstructured":"Mikkelsen MS, Blaakaer J, Petersen LK, Schleiss LG, Iversen LH. Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer. Pleura Peritoneum. 2020;5(4):20200137. https:\/\/doi.org\/10.1515\/pp-2020-0137.","journal-title":"Pleura Peritoneum"},{"key":"13932_CR35","first-page":"3209","volume":"39","author":"RF Ozols","year":"1979","unstructured":"Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 1979;39:3209\u201314.","journal-title":"Cancer Res."},{"key":"13932_CR36","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00280-008-0800-0","volume":"63","author":"K Van Der Speeten","year":"2009","unstructured":"Van Der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol. 2009;63:799\u2013805.","journal-title":"Cancer Chemother Pharmacol."},{"key":"13932_CR37","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1124\/dmd.112.047480","volume":"40","author":"E Salvatorelli","year":"2012","unstructured":"Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, et al. Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis. Drug Metab Dispos. 2012;40:2365\u201373.","journal-title":"Drug Metab Dispos."},{"key":"13932_CR38","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1245\/s10434-007-9718-8","volume":"15","author":"LE Harrison","year":"2008","unstructured":"Harrison LE, Bryan M, Pliner L, Saunders T. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. Ann Surg Oncol. 2008;15:1407\u201313.","journal-title":"Ann Surg Oncol."},{"key":"13932_CR39","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0360-3016(94)90572-X","volume":"29","author":"S Ning","year":"1994","unstructured":"Ning S, Macleod K, Abra RM, Huang AH, Hahn GM. Hyperthermia induces doxorubicin release from long-circulating liposomes and enhances their anti-tumor efficacy. Int J Radiat Oncol Biol Phys. 1994;29:827\u201334.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"13932_CR40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ctrv.2006.07.006","volume":"32","author":"E De Bree","year":"2006","unstructured":"De Bree E, Theodoropoulos PA, Rosing H, Michalakis J, Romanos J, Beijnen JH, et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat Rev. 2006;32:471\u201382.","journal-title":"Cancer Treat Rev."},{"key":"13932_CR41","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ejso.2006.03.008","volume":"32","author":"E De Bree","year":"2006","unstructured":"De Bree E, Rosing H, Michalakis J, Romanos J, Relakis K, Theodoropoulos PA, et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32:666\u201370.","journal-title":"Eur J Surg Oncol."},{"key":"13932_CR42","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1245\/s10434-007-9792-y","volume":"15","author":"E De Bree","year":"2008","unstructured":"De Bree E, Rosing H, Filis D, Romanos J, Melissourgaki M, Daskalakis M, et al. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol. 2008;15:1183\u201392.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"13932_CR43","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.21873\/anticanres.14700","volume":"40","author":"E Debree","year":"2020","unstructured":"Debree E, Katsougkri D, Polioudaki H, Tsangaridou E, Michelakis D, Zoras O, Theodoropoulos P. Hyperthermia during intraperitoneal chemotherapy with paclitaxel or docetaxel for ovarian cancer: is there any benefit? Anticancer Res. 2020;40(12):6769\u201380. https:\/\/doi.org\/10.21873\/anticanres.14700.","journal-title":"Anticancer Res."},{"issue":"5","key":"13932_CR44","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3109\/02656739709023551","volume":"13","author":"RC Rietbroek","year":"1997","unstructured":"Rietbroek RC, Katschinski DM, Reijers MH, Robins HI, Geerdink A, Tutsch K, d\u2019Oleire F, Haveman J. Lack of thermal enhancement for taxanes in vitro. Int J Hyperthermia. 1997;13(5):525\u201333. https:\/\/doi.org\/10.3109\/02656739709023551. (PMID: 9354937).","journal-title":"Int J Hyperthermia."},{"issue":"1","key":"13932_CR45","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.3802\/jgo.2019.30.e3","volume":"30","author":"YJ Lee","year":"2019","unstructured":"Lee YJ, Lee JY, Cho MS, Nam EJ, Kim SW, Kim S, Kim YT. Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study. J Gynecol Oncol. 2019;30(1):e3. https:\/\/doi.org\/10.3802\/jgo.2019.30.e3.","journal-title":"J Gynecol Oncol."},{"issue":"4","key":"13932_CR46","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1245\/aso.2003.08.006","volume":"10","author":"F Mohamed","year":"2003","unstructured":"Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 2003;10(4):463\u20138. https:\/\/doi.org\/10.1245\/aso.2003.08.006. (PMID: 12734097).","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"13932_CR47","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jso.21448","volume":"101","author":"JH Kim","year":"2010","unstructured":"Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, Lee KH, Lee SH, Kim SJ. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol. 2010;101(2):149\u201355. https:\/\/doi.org\/10.1002\/jso.21448. (PMID: 20035540).","journal-title":"J Surg Oncol."},{"key":"13932_CR48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00001813-200302000-00003","volume":"14","author":"E De Bree","year":"2003","unstructured":"De Bree E, Rosing H, Beijnen JH, Romanos J, Michalakis J, Georgoulias V, et al. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs. 2003;14:103\u201310.","journal-title":"Anticancer Drugs."},{"issue":"12","key":"13932_CR49","first-page":"2496","volume":"41","author":"Y Yonemura","year":"2014","unstructured":"Yonemura Y, Canbay E, Sako S, Ishibashi H, Hirano M, Mizumoto A, Takeshita K, Takao N, Ichinose M, Liu Y, Li Y, Ikeda S, Noguchi A, Sai Y. Pharmacokinetics of docetaxel during hyperthermic intraperitoneal chemotherapy for peritoneal metastasis. Gan To Kagaku Ryoho. 2014;41(12):2496\u20139 (PMID: 25731569).","journal-title":"Gan To Kagaku Ryoho."},{"key":"13932_CR50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/026567399285765","volume":"15","author":"M Urano","year":"1999","unstructured":"Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthemia. 1999;15:79\u2013107.","journal-title":"Int J Hyperthemia."},{"key":"13932_CR51","first-page":"827534","volume":"2012","author":"L Bijelic","year":"2012","unstructured":"Bijelic L, Sugarbaker PH, Stuart OA. Hyperthermic intraperitoneal chemotherapy with melphalan: a summary of clinical and pharmacological data in 34 patients. Gastroenterol Res Pract. 2012;2012:827534.","journal-title":"Gastroenterol Res Pract."},{"key":"13932_CR52","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","volume":"13","author":"D Elias","year":"2002","unstructured":"Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267\u201372.","journal-title":"Ann Oncol."},{"key":"13932_CR53","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/SLA.0b013e3182193143","volume":"254","author":"N Pich\u00e9","year":"2011","unstructured":"Pich\u00e9 N, Leblond FA, Sid\u00e9ris L, Pichette V, Drolet P, Fortier LP, et al. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann Surg. 2011;254:138\u201344.","journal-title":"Ann Surg."},{"issue":"6","key":"13932_CR54","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejso.2010.04.005","volume":"36","author":"C Pomel","year":"2010","unstructured":"Pomel C, Ferron G, Lorimier G, Rey A, Lhomme C, Classe JM, Bereder JM, Quenet F, Meeus P, Marchal F, Morice P, Elias D. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial CHIPOVAC study. Eur J Surg Oncol. 2010;36(6):589\u201393. https:\/\/doi.org\/10.1016\/j.ejso.2010.04.005.","journal-title":"Eur J Surg Oncol"},{"key":"13932_CR55","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1245\/s10434-016-5143-1","volume":"23","author":"T Charrier","year":"2016","unstructured":"Charrier T, Passot G, Peron J, Maurice C, Gocevska S, Qu\u00e9net F, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol. 2016;23:2315\u201322.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"13932_CR56","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1245\/s10434-009-0878-6","volume":"19","author":"WP Ceelen","year":"2012","unstructured":"Ceelen WP, Van Nieuwenhove Y, Van Belle S, Denys H, Pattyn P. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol. 2012;19(7):2352\u20139. https:\/\/doi.org\/10.1245\/s10434-009-0878-6. (Epub 2009 Dec 29 PMID: 20039210).","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"13932_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/jso.21732","volume":"103","author":"JS Frenel","year":"2011","unstructured":"Frenel JS, Leux C, Pouplin L, Ferron G, Berton Rigaud D, Bourbouloux E, Dravet F, Jaffre I, Classe JM. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: a pilot study of 31 patients. J Surg Oncol. 2011;103(1):10\u20136. https:\/\/doi.org\/10.1002\/jso.21732. (PMID: 21031424).","journal-title":"J Surg Oncol."},{"issue":"3","key":"13932_CR58","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ygyno.2009.03.004","volume":"113","author":"A Fagotti","year":"2009","unstructured":"Fagotti A, Paris I, Grimolizzi F, Fanfani F, Vizzielli G, Naldini A, Scambia G. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. Gynecol Oncol. 2009;113(3):335\u201340. https:\/\/doi.org\/10.1016\/j.ygyno.2009.03.004. (Epub 2009 Apr 5 PMID: 19345401).","journal-title":"Gynecol Oncol."},{"issue":"10","key":"13932_CR59","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s12094-019-02065-3","volume":"21","author":"I Manzanedo","year":"2019","unstructured":"Manzanedo I, Pereira F, Serrano \u00c1, P\u00e9rez-Viejo E, Mart\u00ednez-Torres B, Carri\u00f3n L, Calzas J. The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study. Clin Transl Oncol. 2019;21(10):1357\u201363. https:\/\/doi.org\/10.1007\/s12094-019-02065-3. (Epub 2019 Feb 20 PMID: 30788835).","journal-title":"Clin Transl Oncol."},{"key":"13932_CR60","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/bjc.2014.602","volume":"112","author":"L Ansaloni","year":"2015","unstructured":"Ansaloni L, Coccolini F, Morosi L, et al. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer. 2015;112:306\u201312. https:\/\/doi.org\/10.1038\/bjc.2014.602.","journal-title":"Br J Cancer."},{"key":"13932_CR61","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.1245\/s10434-012-2510-4","volume":"19","author":"N Bakrin","year":"2012","unstructured":"Bakrin N, Cotte E, Golfier F, Gilly FN, Freyer G, Helm W, Glehen O, Bereder JM. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol. 2012;19:4052\u20138. https:\/\/doi.org\/10.1245\/s10434-012-2510-4.","journal-title":"Ann Surg Oncol."},{"key":"13932_CR62","doi-asserted-by":"publisher","first-page":"185092","DOI":"10.1155\/2011\/185092r","volume":"2011","author":"K Van der Speeten","year":"2011","unstructured":"Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Pharmacokinetic study of perioperative intravenous Ifosfamide. Int J Surg Oncol. 2011;2011:185092. https:\/\/doi.org\/10.1155\/2011\/185092r.","journal-title":"Int J Surg Oncol."},{"issue":"2","key":"13932_CR63","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ygyno.2011.05.004","volume":"122","author":"M Deraco","year":"2011","unstructured":"Deraco M, Kusamura S, Virz\u00ec S, Puccio F, Macr\u00ec A, Famulari C, Solazzo M, Bonomi S, Iusco DR, Baratti D. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol. 2011;122(2):215\u201320. https:\/\/doi.org\/10.1016\/j.ygyno.2011.05.004. (Epub 2011 Jun 12 PMID: 21665254).","journal-title":"Gynecol Oncol."},{"key":"13932_CR64","first-page":"161862","volume":"2011","author":"PH Sugarbaker","year":"2011","unstructured":"Sugarbaker PH, Stuart OA, Bijelic L. Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data. Int J Surg Oncol. 2011;2011:161862.","journal-title":"Int J Surg Oncol."},{"issue":"1","key":"13932_CR65","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3978\/j.issn.2078-6891.2015.105","volume":"7","author":"PH Sugarbaker","year":"2016","unstructured":"Sugarbaker PH, Van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol. 2016;7(1):29\u201344. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2015.105. (PMID: 26941982; PMCID: PMC4754302).","journal-title":"J Gastrointest Oncol."},{"issue":"480","key":"13932_CR66","first-page":"e1","volume":"205","author":"MB Schiavone","year":"2011","unstructured":"Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205(480):e1-8.","journal-title":"Am J Obstet Gynecol."},{"key":"13932_CR67","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/cncr.24915","volume":"116","author":"A Bamias","year":"2010","unstructured":"Bamias A, Psaltopoulou T, Sotiropoulou M, et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010;116:1462\u20138.","journal-title":"Cancer."},{"key":"13932_CR68","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1245\/s10434-018-6464-z","volume":"25","author":"F Mercier","year":"2018","unstructured":"Mercier F, Bakrin N, Bartlett DL, et al. Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multi-institutional cohort from PSOGI and BIG-RENAPE. Ann Surg Oncol. 2018;25:1668\u201375. https:\/\/doi.org\/10.1245\/s10434-018-6464-z.","journal-title":"Ann Surg Oncol."},{"key":"13932_CR69","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s002800050870","volume":"43","author":"M Steller","year":"1999","unstructured":"Steller M, Egorin M, Trimble E, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol. 1999;43:106\u201314. https:\/\/doi.org\/10.1007\/s002800050870.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"1","key":"13932_CR70","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/CAD.0b013e3282f07791","volume":"19","author":"MN Kirstein","year":"2008","unstructured":"Kirstein MN, Root SA, Moore MM, Wieman KM, Williams BW, Jacobson PA, Marker PH, Tuttle TM. Exposure-response relationships for oxaliplatin-treated colon cancer cells. Anticancer Drugs. 2008;19(1):37\u201344. https:\/\/doi.org\/10.1097\/CAD.0b013e3282f07791. (PMID: 18043128).","journal-title":"Anticancer Drugs."},{"key":"13932_CR71","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00228-012-1405-4","volume":"69","author":"PH Cashin","year":"2013","unstructured":"Cashin PH, Ehrsson H, Wallin I, et al. Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis. Eur J Clin Pharmacol. 2013;69:533\u201340. https:\/\/doi.org\/10.1007\/s00228-012-1405-4.","journal-title":"Eur J Clin Pharmacol."},{"issue":"9","key":"13932_CR72","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1245\/s10434-011-1651-1","volume":"18","author":"E Cotte","year":"2011","unstructured":"Cotte E, Passot G, Tod M, Bakrin N, Gilly FN, Steghens A, Mohamed F, Glehen O. Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study. Ann Surg Oncol. 2011;18(9):2599\u2013603. https:\/\/doi.org\/10.1245\/s10434-011-1651-1. (Epub 2011 Mar 19 PMID: 21424369).","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"13932_CR73","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","volume":"13","author":"D Elias","year":"2002","unstructured":"Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13(2):267\u201372.","journal-title":"Ann Oncol."},{"key":"13932_CR74","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1245\/s10434-008-9967-1","volume":"15","author":"JH Stewart","year":"2008","unstructured":"Stewart JH, Shen P, Russell GB, et al. A Phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancer. Ann Surg Oncol. 2008;15:2137\u201345.","journal-title":"Ann Surg Oncol."},{"key":"13932_CR75","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/02656739709023545","volume":"13","author":"JV Hettinga","year":"1997","unstructured":"Hettinga JV, Konings AW, Kampinga HH. Reduction of cellular cisplatin resistance by hyperthermia: a review. Int J Hyperth. 1997;13:439\u201357.","journal-title":"Int J Hyperth."},{"issue":"1","key":"13932_CR76","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.3802\/jgo.2022.33.e1","volume":"33","author":"R Farrell","year":"2022","unstructured":"Farrell R, Burling M, Lee YC, Pather S, Robledo K, Mercieca-Bebber R, Stockler M. HyNOVA Protocol Steering Committee. Clinical trial protocol for HyNOVA: hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901\/2020). J Gynecol Oncol. 2022;33(1):e1. https:\/\/doi.org\/10.3802\/jgo.2022.33.e1. (Epub 2021 Oct 18 PMID: 34783204 PMCID: PMC8728663).","journal-title":"J Gynecol Oncol."},{"issue":"5","key":"13932_CR77","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/cncr.21708","volume":"106","author":"S Kusamura","year":"2006","unstructured":"Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106(5):1144\u201353. https:\/\/doi.org\/10.1002\/cncr.21708. (PMID: 16456817).","journal-title":"Cancer."},{"issue":"12","key":"13932_CR78","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1023\/A:1008296202198","volume":"8","author":"RE van Rijswijk","year":"1997","unstructured":"van Rijswijk RE, Hoekman K, Burger CW, et al. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. Ann Oncol. 1997;8(12):1235\u201341.","journal-title":"Ann Oncol."},{"issue":"3","key":"13932_CR79","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1124\/jpet.105.087601","volume":"314","author":"DT Dickey","year":"2005","unstructured":"Dickey DT, Wu YJ, Muldoon LL, Neuwelt EA. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in\u00a0vivo levels. J Pharmacol Exp Ther. 2005;314(3):1052\u20138.","journal-title":"J Pharmacol Exp Ther."},{"issue":"4","key":"13932_CR80","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/clinchem\/32.4.641","volume":"32","author":"F Elferink","year":"1986","unstructured":"Elferink F, van der Vijgh WJ, Klein I, Pinedo HM. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. Clin Chem. 1986;32(4):641\u20135 (PMID: 3513991).","journal-title":"Clin Chem."},{"issue":"6","key":"13932_CR81","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ejso.2015.08.174","volume":"42","author":"M Ceresoli","year":"2016","unstructured":"Ceresoli M, Coccolini F, Ansaloni L. HIPEC and nephrotoxicity: a cisplatin induced effect? Eur J Surg Oncol. 2016;42(6):909\u201310. https:\/\/doi.org\/10.1016\/j.ejso.2015.08.174. (Epub 2016 Feb 26 PMID: 26965304).","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"13932_CR82","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3802\/jgo.2015.26.1.54","volume":"26","author":"F Coccolini","year":"2015","unstructured":"Coccolini F, Campanati L, Catena F, Ceni V, Ceresoli M, Jimenez Cruz J, Lotti M, Magnone S, Napoli J, Rossetti D, De Iaco P, Frigerio L, Pinna A, Runnebaum I, Ansaloni L. Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol. 2015;26(1):54\u201361. https:\/\/doi.org\/10.3802\/jgo.2015.26.1.54. (Epub 2014 Nov 3 PMID: 25376916 PMCID: PMC4302286).","journal-title":"J Gynecol Oncol."},{"issue":"5","key":"13932_CR83","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/00000421-198610000-00016","volume":"9","author":"M Markman","year":"1986","unstructured":"Markman M, Cleary S, Howell SB. Hypomagnesemia following high-dose intracavitary cisplatin with systemically administered sodium thiosulfate. Am J Clin Oncol. 1986;9(5):440\u20133. https:\/\/doi.org\/10.1097\/00000421-198610000-00016. (PMID: 3776908).","journal-title":"Am J Clin Oncol."},{"issue":"1","key":"13932_CR84","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0959-8049(05)80017-6","volume":"30","author":"JP Guastalla","year":"1994","unstructured":"Guastalla JP, Vermorken JB, Wils JA, et al. Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy-a phase II study of the EORTC Gynaecological Cancer Cooperative Group. Eur J Cancer. 1994;30(1):45\u20139.","journal-title":"Eur J Cancer."},{"key":"13932_CR85","doi-asserted-by":"publisher","first-page":"100734","DOI":"10.1016\/j.gore.2021.100734","volume":"36","author":"K Patel","year":"2021","unstructured":"Patel K, Asare A, Moufarrij S, Costales AB. Sodium thiosulfate for postoperative cisplatin induced nephrotoxicity following hyperthermic intraperitoneal chemotherapy: a case report. Gynecol Oncol Rep. 2021;36:100734. https:\/\/doi.org\/10.1016\/j.gore.2021.100734. (PMID: 33732850; PMCID: PMC7941151).","journal-title":"Gynecol Oncol Rep."},{"issue":"1","key":"13932_CR86","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/02656736.2020.1795277","volume":"37","author":"N Laplace","year":"2020","unstructured":"Laplace N, Kepenekian V, Friggeri A, Vassal O, Ranchon F, Rioufol C, Gertych W, Villeneuve L, Glehen O, Bakrin N. Sodium thiosulfate protects from renal impairment following hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin. Int J Hyperthermia. 2020;37(1):897\u2013902. https:\/\/doi.org\/10.1080\/02656736.2020.1795277.","journal-title":"Int J Hyperthermia."},{"key":"13932_CR87","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1245\/s10434-021-10508-x","volume":"29","author":"A Kurreck","year":"2022","unstructured":"Kurreck A, Gronau F, Alberto Vilchez ME, et al. Sodium thiosulfate reduces acute kidney injury in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with cisplatin: a single-center observational study. Ann Surg Oncol. 2022;29:152\u201362. https:\/\/doi.org\/10.1245\/s10434-021-10508-x.","journal-title":"Ann Surg Oncol."},{"key":"13932_CR88","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1185\/030079906X167633","volume":"23","author":"A Tejedor","year":"2007","unstructured":"Tejedor A, Torres AM, Castilla M, Lazaro JA, de Lucas C, Caramelo C. Cilastatin protection against cyclosporin A-induced nephrotoxicity: clinical evidence. Curr Med Res Opin. 2007;23:505\u201313.","journal-title":"Curr Med Res Opin."},{"key":"13932_CR89","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00007890-199403270-00017","volume":"57","author":"A Markewitz","year":"1994","unstructured":"Markewitz A, Hammer C, Pfeiffer M, Zahn S, Drechsel J, Reichenspurner H, Reichart B. Reduction of cyclosporine induced nephrotoxicity by cilastatin following clinical heart transplantation. Transplantation. 1994;57:865\u201370.","journal-title":"Transplantation."},{"key":"13932_CR90","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/jpet.110.165779","volume":"334","author":"S Cama\u00f1o","year":"2010","unstructured":"Cama\u00f1o S, Lazaro A, Moreno-Gordaliza E, Torres AM, de Lucas C, Humanes B, Lazaro JA, Gomez-Gomez MM, Bosca L, Tejedor A. Cilastatin attenuates cisplatin-induced proximal tubular cell damage. J Pharmacol Exp Ther. 2010;334:419\u201329.","journal-title":"J Pharmacol Exp Ther."},{"key":"13932_CR91","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2012.199","volume":"82","author":"B Humanes","year":"2012","unstructured":"Humanes B, Lazaro A, Cama\u00f1o S, Moreno-Gordaliz E, Lazaro JA, Blanco-Codesido M, Lara JM, Ortiz A, Gomez-Gomez MM, Mart\u00edn-Vasallo P, et al. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. Kidney Int. 2012;82:652\u201363.","journal-title":"Kidney Int."},{"issue":"3","key":"13932_CR92","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3390\/ijms22031239","volume":"22","author":"M Zaballos","year":"2021","unstructured":"Zaballos M, Power M, Canal-Alonso MI, Gonz\u00e1lez-Nicol\u00e1s M\u00c1, Vasquez-Jimenez W, Lozano-Lominchar P, Cabrerizo-Torrente P, Palencia-Garc\u00eda N, Gago-Quiroga S, Ginel-Feito MD, Jim\u00e9nez C, L\u00e1zaro A, Gonz\u00e1lez-Bay\u00f3n L. Effect of cilastatin on cisplatin-induced nephrotoxicity in patients undergoing hyperthermic intraperitoneal chemotherapy. Int J Mol Sci. 2021;22(3):1239. https:\/\/doi.org\/10.3390\/ijms22031239. (PMID: 33513824 PMCID: PMC7865672).","journal-title":"Int J Mol Sci."},{"issue":"4","key":"13932_CR93","first-page":"207","volume":"92","author":"M Vaira","year":"2001","unstructured":"Vaira M, Barone R, Aghemo B, Mioli PR, De Simone M. Protezione renale con amifostine durante chemioipertermia intraperatoria peritoneale (CIIP) con cisplatino (CDDP) per carcinosi peritoneale. Studio fase I [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study]. Minerva Med. 2001;92(4):207\u201311 (PMID: 11535965).","journal-title":"Minerva Med."},{"issue":"6","key":"13932_CR94","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.ejso.2016.09.008","volume":"43","author":"C Rasp\u00e9","year":"2017","unstructured":"Rasp\u00e9 C, Fl\u00f6ther L, Schneider R, Bucher M, Piso P. Best practice for perioperative management of patients with cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2017;43(6):1013\u201327. https:\/\/doi.org\/10.1016\/j.ejso.2016.09.008. (Epub 2016 Sep 28 PMID: 27727026).","journal-title":"Eur J Surg Oncol."},{"key":"13932_CR95","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12885-018-4365-y","volume":"18","author":"S Liutkauskiene","year":"2018","unstructured":"Liutkauskiene S, Grizas S, Jureniene K, et al. Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes. BMC Cancer. 2018;18:453. https:\/\/doi.org\/10.1186\/s12885-018-4365-y.","journal-title":"BMC Cancer."},{"key":"13932_CR96","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12885-018-4380-z","volume":"18","author":"S Munker","year":"2018","unstructured":"Munker S, Gerken M, Fest P, et al. Chemotherapy for metastatic colon cancer: no effect on survival when the dose is reduced due to side effects. BMC Cancer. 2018;18:455. https:\/\/doi.org\/10.1186\/s12885-018-4380-z.","journal-title":"BMC Cancer."},{"issue":"8","key":"13932_CR97","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/sj.bjc.6600139","volume":"86","author":"H Gurney","year":"2002","unstructured":"Gurney H. How to calculate the dose of chemotherapy. Br J Cancer. 2002;86(8):1297\u2013302. https:\/\/doi.org\/10.1038\/sj.bjc.6600139. (PMID: 11953888 PMCID: PMC2375356).","journal-title":"Br J Cancer."},{"key":"13932_CR98","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2486\/indhealth.2014-0025","volume":"53","author":"AF Villa","year":"2015","unstructured":"Villa AF, El Balkhi S, Aboura R, Sageot H, Hasni-Pichard H, Pocard M, Elias D, Joly N, Payen D, Blot F, Poupon J, Garnier R. Evaluation of oxaliplatin exposure of healthcare workers during heated intraperitoneal perioperative chemotherapy (HIPEC). Ind Health. 2015;53:28\u201337.","journal-title":"Ind Health."},{"key":"13932_CR99","first-page":"431","volume":"1","author":"D Elias","year":"2000","unstructured":"Elias D, Antoun S, Goharin A, Otmany AE, Puizillout JM, Lasser P. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig. 2000;1:431\u20139.","journal-title":"Int J Surg Investig."},{"issue":"3","key":"13932_CR100","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jso.25277","volume":"119","author":"NA Alzahrani","year":"2019","unstructured":"Alzahrani NA, Valle SJ, Fisher OM, et al. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional experience. J Surg Oncol. 2019;119(3):336\u201346.","journal-title":"J Surg Oncol."},{"key":"13932_CR101","doi-asserted-by":"publisher","first-page":"666","DOI":"10.20517\/cdr.2020.27","volume":"3","author":"TP Batista","year":"2020","unstructured":"Batista TP, Dal Molin GZ. Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer? Cancer Drug Resist. 2020;3:666\u201371. https:\/\/doi.org\/10.20517\/cdr.2020.27.","journal-title":"Cancer Drug Resist."},{"key":"13932_CR102","doi-asserted-by":"crossref","first-page":"9851","DOI":"10.1073\/pnas.1101053108","volume":"108","author":"PM Krawczyk","year":"2011","unstructured":"Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci U S A. 2011;108:9851\u20136.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"13932_CR103","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/0008-5472.CAN-15-2908","volume":"76","author":"L Schaaf","year":"2016","unstructured":"Schaaf L, Schwab M, Ulmer C, Heine S, M\u00fcrdter TE, et al. Hyperthermia synergizes with chemotherapy by inhibiting PARP1-dependent DNA replication arrest. Cancer Res. 2016;76:2868\u201375.","journal-title":"Cancer Res."},{"key":"13932_CR104","doi-asserted-by":"publisher","first-page":"100518","DOI":"10.1016\/j.ctarc.2022.100518","volume":"31","author":"V Ghirardi","year":"2022","unstructured":"Ghirardi V, De Felice F, D\u2019Indinosante M, Bernardini F, Giudice MT, Fagotti A, Scambia G. Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: is BRCA mutational status making the difference? Cancer Treat Res Commun. 2022;31:100518. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100518. (Epub 2022 Jan 14 PMID: 35065323).","journal-title":"Cancer Treat Res Commun."},{"issue":"8","key":"13932_CR105","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/ijc.34124","volume":"151","author":"SN Koole","year":"2022","unstructured":"Koole SN, Schouten PC, Hauke J, et al. Effect of HIPEC according to HRD\/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial. Int J Cancer. 2022;151(8):1394\u2013404. https:\/\/doi.org\/10.1002\/ijc.34124.","journal-title":"Int J Cancer."},{"issue":"12","key":"13932_CR106","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2147\/OTT.S155425","volume":"8","author":"C Marchetti","year":"2019","unstructured":"Marchetti C, Muzii L, Romito A, Benedetti PP. First-line treatment of women with advanced ovarian cancer: focus on bevacizumab. Onco Targets Ther. 2019;8(12):1095\u2013103. https:\/\/doi.org\/10.2147\/OTT.S155425. (PMID: 30799939 PMCID: PMC6371937).","journal-title":"Onco Targets Ther."},{"key":"13932_CR107","doi-asserted-by":"publisher","unstructured":"Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K 2009 Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every weeks for advanced ovarian cancer a phase 3, open-label, randomised controlled trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(09)61157-0","DOI":"10.1016\/S0140-6736(09)61157-0"},{"issue":"3","key":"13932_CR108","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ygyno.2016.04.016","volume":"141","author":"Z Feng","year":"2016","unstructured":"Feng Z, Wen H, Bi R, Yang W, Wu X. Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer. Gynecol Oncol. 2016;141(3):466\u201370. https:\/\/doi.org\/10.1016\/j.ygyno.2016.04.016. (Epub 2016 Apr 23 PMID: 27098361).","journal-title":"Gynecol Oncol."},{"issue":"29","key":"13932_CR109","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1200\/JCO.2017.73.4293","volume":"35","author":"S Pignata","year":"2017","unstructured":"Pignata S, Scambia G, Bologna A, Signoriello S, Vergote IB, Wagner U, Lorusso D, et al. Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1 GCIG study. J Clin Oncol. 2017;35(29):3347\u201353. https:\/\/doi.org\/10.1200\/JCO.2017.73.4293. (Epub 2017 Aug 21 PMID: 28825853).","journal-title":"J Clin Oncol."},{"issue":"22","key":"13932_CR110","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","volume":"33","author":"S B\u00f6hm","year":"2015","unstructured":"B\u00f6hm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB, Singh N. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015;33(22):2457\u201363. https:\/\/doi.org\/10.1200\/JCO.2014.60.5212. (Epub 2015 Jun 29 PMID: 26124480).","journal-title":"J Clin Oncol."},{"issue":"1","key":"13932_CR111","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1515\/pp-2016-0006","volume":"1","author":"F Gremonprez","year":"2016","unstructured":"Gremonprez F, Willaert W, Ceelen W. Animal models of colorectal peritoneal metastasis. Pleura Peritoneum. 2016;1(1):23\u201343. https:\/\/doi.org\/10.1515\/pp-2016-0006.","journal-title":"Pleura Peritoneum"},{"issue":"1","key":"13932_CR112","doi-asserted-by":"publisher","first-page":"20180101","DOI":"10.1515\/pp-2018-0101","volume":"3","author":"BJ Moran","year":"2018","unstructured":"Moran BJ, Tzivanakis A. The concept of \u201cobstruction-free survival\u201d as an outcome measure in advanced colorectal cancer management. Pleura Peritoneum. 2018;3(1):20180101. https:\/\/doi.org\/10.1515\/pp-2018-0101. (PMID: 30911651 PMCID:PMC6404992).","journal-title":"Pleura Peritoneum."},{"issue":"5","key":"13932_CR113","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/ijgc-2023-004411","volume":"33","author":"DJ Brennan","year":"2023","unstructured":"Brennan DJ, Driel WJV, Zivanovic O. The necessity to adhere to evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian cancer. Int J Gynecol Cancer. 2023;33(5):851\u20132. https:\/\/doi.org\/10.1136\/ijgc-2023-004411. (PMID: 36898700).","journal-title":"Int J Gynecol Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13932-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13932-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13932-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T10:04:00Z","timestamp":1699178640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13932-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":113,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["13932"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13932-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"assertion":[{"value":"3 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Olivier Glehen is a consultant for Gamida Tech. The other authors have no disclosures. The authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}